| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 0 | 13.118 | 20.793 | 36.630 | 50.664 | 75.016 | 64.330 |
| Total Income - EUR | - | - | - | 0 | 13.118 | 20.815 | 36.636 | 50.668 | 75.016 | 64.330 |
| Total Expenses - EUR | - | - | - | 10 | 2.419 | 2.439 | 1.837 | 6.230 | 11.677 | 17.677 |
| Gross Profit/Loss - EUR | - | - | - | -10 | 10.699 | 18.375 | 34.799 | 44.438 | 63.339 | 46.653 |
| Net Profit/Loss - EUR | - | - | - | -10 | 10.306 | 17.752 | 33.700 | 43.273 | 62.589 | 44.723 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Sha Evolution Oncology S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 687 | 936 | 1.700 | 1.119 | 2.278 | 4.507 |
| Current Assets | - | - | - | 40 | 9.742 | 27.246 | 34.606 | 44.705 | 63.318 | 47.871 |
| Inventories | - | - | - | 0 | 521 | 0 | 1.052 | 1.303 | 1.386 | 1.633 |
| Receivables | - | - | - | 0 | 8.231 | 20.862 | 21.845 | 33.536 | 39.707 | 25.504 |
| Cash | - | - | - | 40 | 990 | 6.384 | 11.709 | 9.866 | 22.224 | 20.734 |
| Shareholders Funds | - | - | - | 33 | 10.339 | 27.894 | 33.740 | 43.313 | 62.630 | 44.763 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 6 | 90 | 288 | 2.566 | 2.510 | 2.966 | 7.615 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8610 - 8610" | |||||||||
| CAEN Financial Year |
8610
|
|||||||||
Comments - Sha Evolution Oncology S.r.l.